<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00141817</url>
  </required_header>
  <id_info>
    <org_study_id>3001B3-334</org_study_id>
    <secondary_id>B1791059</secondary_id>
    <nct_id>NCT00141817</nct_id>
  </id_info>
  <brief_title>Study Evaluating Pantoprazole in Children With GERD</brief_title>
  <official_title>A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the PK profile, safety and tolerability of
      single and multiple doses of pantoprazole in children aged 1 through 11 years with
      endoscopically proven GERD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]</measure>
    <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (0-t).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</measure>
    <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
    <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal-Phase Volume of Distribution (Vz/F)</measure>
    <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
    <description>Vz/F was calculated as the ratio of clearance (CL) to terminal disposition rate constant (λz).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations After Multiple Doses</measure>
    <time_frame>Hours 2 and 4 on Day 7</time_frame>
  </primary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole for approximately 9 weeks.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endoscopically proven GERD diagnosed within 6 months before study entry.

          -  Weight must be equal to or over 8.3 kg; for subjects 6 years or greater, weight must
             be equal to or under 25 kg

        Exclusion Criteria:

          -  History of GI disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption,
             Eosinophilic esophagitis

          -  Subjects 6-11 years old unable to swallow tablets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <results_first_submitted>November 23, 2011</results_first_submitted>
  <results_first_submitted_qc>November 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2011</results_first_posted>
  <last_update_submitted>November 23, 2011</last_update_submitted>
  <last_update_submitted_qc>November 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Reflux Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pantoprazole 0.6 mg/kg Spheroids</title>
          <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
        </group>
        <group group_id="P2">
          <title>Pantoprazole 1.2 mg/kg Spheroids</title>
          <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
        </group>
        <group group_id="P3">
          <title>Pantoprazole 0.6 mg/kg Tablets</title>
          <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
        </group>
        <group group_id="P4">
          <title>Pantoprazole 1.2 mg/kg Tablets</title>
          <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pantoprazole 0.6 mg/kg Spheroids</title>
          <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
        </group>
        <group group_id="B2">
          <title>Pantoprazole 1.2 mg/kg Spheroids</title>
          <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
        </group>
        <group group_id="B3">
          <title>Pantoprazole 0.6 mg/kg Tablets</title>
          <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
        </group>
        <group group_id="B4">
          <title>Pantoprazole 1.2 mg/kg Tablets</title>
          <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.86" spread="1.46"/>
                    <measurement group_id="B2" value="2.80" spread="1.55"/>
                    <measurement group_id="B3" value="8.55" spread="1.97"/>
                    <measurement group_id="B4" value="8.77" spread="1.09"/>
                    <measurement group_id="B5" value="6.41" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
        <population>Single-Dose Valid-for-Evaluation Population: Randomized participants who took 1 dose of pantoprazole and had at least 4 single-dose blood samples for pharmacokinetic (PK) analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>Single-Dose Valid-for-Evaluation Population: Randomized participants who took 1 dose of pantoprazole and had at least 4 single-dose blood samples for pharmacokinetic (PK) analyses.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="127"/>
                    <measurement group_id="O2" value="798" spread="729"/>
                    <measurement group_id="O3" value="1643" spread="1229"/>
                    <measurement group_id="O4" value="2067" spread="1320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
        <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.69"/>
                    <measurement group_id="O2" value="2.71" spread="1.25"/>
                    <measurement group_id="O3" value="2.08" spread="0.75"/>
                    <measurement group_id="O4" value="2.03" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]</title>
        <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (0-t).</description>
        <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
        <population>Single-Dose Valid-for-Evaluation Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]</title>
          <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (0-t).</description>
          <population>Single-Dose Valid-for-Evaluation Population.</population>
          <units>nanogram hour per milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.96" spread="197.54"/>
                    <measurement group_id="O2" value="2273.96" spread="1885.68"/>
                    <measurement group_id="O3" value="2448.61" spread="2007.21"/>
                    <measurement group_id="O4" value="3190.96" spread="2137.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
        <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
        <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
          <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
          <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.29" spread="146.41"/>
                    <measurement group_id="O2" value="2448.08" spread="2170.48"/>
                    <measurement group_id="O3" value="2497.13" spread="2099.64"/>
                    <measurement group_id="O4" value="3782.49" spread="1837.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life (t1/2)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
        <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="7.39"/>
                    <measurement group_id="O2" value="1.68" spread="0.64"/>
                    <measurement group_id="O3" value="0.77" spread="0.22"/>
                    <measurement group_id="O4" value="0.70" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F)</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
        <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F)</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
          <units>liter per hour per kilogram (L/h/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="1.27"/>
                    <measurement group_id="O2" value="1.28" spread="1.16"/>
                    <measurement group_id="O3" value="0.41" spread="0.30"/>
                    <measurement group_id="O4" value="0.40" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal-Phase Volume of Distribution (Vz/F)</title>
        <description>Vz/F was calculated as the ratio of clearance (CL) to terminal disposition rate constant (λz).</description>
        <time_frame>Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose</time_frame>
        <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal-Phase Volume of Distribution (Vz/F)</title>
          <description>Vz/F was calculated as the ratio of clearance (CL) to terminal disposition rate constant (λz).</description>
          <population>Single-Dose Valid-for-Evaluation Population. Participants analyzed=number of participants with available data.</population>
          <units>liter per kilogram (L/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.22" spread="14.68"/>
                    <measurement group_id="O2" value="2.89" spread="2.92"/>
                    <measurement group_id="O3" value="0.43" spread="0.30"/>
                    <measurement group_id="O4" value="0.40" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentrations After Multiple Doses</title>
        <time_frame>Hours 2 and 4 on Day 7</time_frame>
        <population>Multiple-Dose Valid-for-Evaluation Population: Randomized participants who had concentration evaluations of pantoprazole either at 2 hours or at 4 hours after single dose and after at least 5 consecutive doses. n=participants who had data available at that specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 0.6 mg/kg Spheroids</title>
            <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole 1.2 mg/kg Spheroids</title>
            <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole 0.6 mg/kg Tablets</title>
            <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
          <group group_id="O4">
            <title>Pantoprazole 1.2 mg/kg Tablets</title>
            <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations After Multiple Doses</title>
          <population>Multiple-Dose Valid-for-Evaluation Population: Randomized participants who had concentration evaluations of pantoprazole either at 2 hours or at 4 hours after single dose and after at least 5 consecutive doses. n=participants who had data available at that specific time point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 2 on Day 7 (n=5, 8, 10, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.30" spread="222.08"/>
                    <measurement group_id="O2" value="486.49" spread="605.22"/>
                    <measurement group_id="O3" value="592.32" spread="914.57"/>
                    <measurement group_id="O4" value="2337.89" spread="1817.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4 on Day 7 (n=6, 8, 10, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503.25" spread="1087.91"/>
                    <measurement group_id="O2" value="207.23" spread="211.92"/>
                    <measurement group_id="O3" value="123.83" spread="163.78"/>
                    <measurement group_id="O4" value="200.78" spread="209.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pantoprazole 0.6 mg/kg Spheroids</title>
          <description>Pantoprazole 0.6 mg/kg Spheroids for Participants Aged &lt;6 years</description>
        </group>
        <group group_id="E2">
          <title>Pantoprazole 1.2 mg/kg Spheroids</title>
          <description>Pantoprazole 1.2 mg/kg Spheroids for Participants Aged &lt;6 years</description>
        </group>
        <group group_id="E3">
          <title>Pantoprazole 0.6 mg/kg Tablets</title>
          <description>Pantoprazole 0.6 mg/kg Tablets for Participants Aged &gt;=6 years</description>
        </group>
        <group group_id="E4">
          <title>Pantoprazole 1.2 mg/kg Tablets</title>
          <description>Pantoprazole 1.2 mg/kg Tablets for Participants Aged &gt;=6 years</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Accidental injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperlipemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal/changed behavior</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Contact dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

